Polymer lipid compound and composition, preparation and application thereof

By developing polymer lipid compounds based on bileic acid derivatives, combining PEG lipids, new lipid nanoparticles are solved, and the problem of bare RNA is difficult to enter and easily degrade in cells, improving the delivery efficiency of nucleic acid drugs and Stability, providing a more effective drug delivery system.

CN118930839APending Publication Date: 2024-11-12SUZHOU HEALIRNA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410584846.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Nude RNA is difficult to enter cells and is easily degraded by RNA enzymes, and existing lipid nanoparticles (LNPs) have challenges in delivery and stability, especially in the intracellular circulation time and drug delivery efficiency.

Method used

Developing polymer lipid compounds based on bile acid or derivatives thereof to form new lipid nanoparticles by binding to PEG lipids, providing a new delivery vehicle to improve intracellular uptake and stability of nucleic acid drugs.

Benefits of technology

It improves the circulation time of nucleic acid drugs in the body and the delivery efficiency in cells, provides a more effective drug delivery system, and enhances the bioavailability and targeting of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930839A_ABST
    Figure CN118930839A_ABST
Patent Text Reader

Abstract

The invention discloses a polymer lipid compound with a general formula as well as a composition, preparation and application of the polymer lipid compound. The polymer lipid compound is a compound based on cholic acid or a derivative of the cholic acid, or pharmaceutically available salt, prodrug or stereoisomer of the cholic acid. The polymer lipid compound and the composition thereof can provide more carrier choices for delivery of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies, small molecule drugs and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and specifically to a class of polymer lipid compounds and compositions, preparation and uses thereof, especially their application in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs. Background Art

[0002] Nucleic acid drugs refer to artificially designed DNA or RNA with disease prevention or treatment functions. They act on pathogenic target genes or target mRNAs to regulate the expression of pathogenic genes from the source, thereby achieving the purpose of disease prevention or treatment. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs can inhibit pathological proteins from the source, and have the advantages of significant medicinal effects, rapid production, strong target specificity, and short research and development cycle. Nucleic acid drugs mainly include antisense oligonucleotide (ASO), small interference RNA (siRNA), microRNA (miRNA), messenger RNA (mRNA), etc.

[0003] However, naked RNA is a negatively charged hydrophilic macromolecule that is difficult to enter cells due to electrostatic repulsion of the cell membrane and is easily degraded by RNases in the body. Therefore, a delivery carrier is required to enter cells. Lipid nanoparticles (LNPs) have been successfully used as a delivery platform for RNA vaccines and therapies.

[0004] Polymer-modified lipids (e.g., PEG lipids) are an important component in LNPs for regulating half-life and cellular uptake. When LNPs are assembled, PEG chains are located on the outer shell of the nanoparticles due to their hydrophilicity and large size. Like other nanocarriers, PEG provides an outer polymer layer for LNPs to prevent serum protein adsorption and uptake by the mononuclear phagocyte system, extending the circulation time in the body. PEG can also prevent the aggregation of nanoparticles during storage and in the blood. In addition, the amount of PEG lipids may determine the size of the particles. Another potential purpose of PEG lipids is to achieve surface functionalization of LNPs. Functionalized PEG lipids can biocouple LNPs with ligands or biomacromolecules.

[0005] The invention develops a new polymer lipid, which provides a new delivery carrier for nucleic acid drugs. Summary of the invention

[0006] The present invention provides a new class of polymer lipid compounds for delivering therapeutic or preventive drugs, namely, polymer lipids based on bile acid or its derivatives, which enrich the types of polymer lipid compounds and provide more options for the delivery of nucleic acid drugs, gene vaccines, peptides, proteins, antibodies and small molecule drugs.

[0007] In one aspect, the present invention provides a polymer lipid compound of the following general formula, or a pharmaceutically acceptable salt thereof, including stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs. Specifically, the "pharmaceutically acceptable salt thereof" refers to an acid addition salt or a base addition salt; the general formula is as follows:

[0008]

[0009] R1 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl, alkane containing nitrogen atom, alkene containing nitrogen atom, alkane containing oxygen atom

[0010] R2 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl, alkane containing nitrogen atom, alkene containing nitrogen atom, alkane containing oxygen atom

[0011] R3 = hydroxyl, halogen, alkane, alkene, alkyne

[0012] R4=hydrogen atom, small molecule, antibody, peptide, protein, nucleic acid, carbohydrate

[0013] X = PEG (polyethylene glycol), polysarcosine derivatives, chitosan derivatives, hyaluronic acid derivatives, dextran, polylactic acid, polyamino acid-modified phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, dialkylglycerol

[0014] L1, L2 = the same or different, linear, branched alkyl chains or heterocyclic compounds, with one or more of amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphoric acid, and carbonate at both ends

[0015] Specifically, the polymer lipid compound is a polymer lipid based on bile acid or its derivatives; wherein bile acid or its derivatives are selected from cholic acid, obeticholic acid, ursodeoxycholic acid, ursolic acid, 3β-hydroxy-D5-cholenic acid, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, taurocholic acid, 5β-cholic acid, dehydrocholic acid, hyocholic acid, glycochenodeoxycholic acid, tauroursodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium tauroursodeoxycholate, sodium dehydrocholate, sodium cholate, sodium deoxyglycocholate, sodium tauroursodeoxycholate, sodium tauroursodeoxycholate, sodium tauroursodeoxycholate, sodium glycocholic acid sodium salt, taurocholic acid-3-sulfate disodium salt, sodium tauroursodeoxycholate and sodium taurolithocholate.

[0016] Specifically, the lipid compound is ursodeoxycholic acid or its derivatives, or lithocholic acid or its derivatives.

[0017] Specifically, the lipid compound is selected from one or more ursodeoxycholic acid derivative lipid compounds, or one or more obeticholic acid derivative lipid compounds, one or more cholic acid derivative lipid compounds, one or more hyodeoxycholic acid derivative lipid compounds, and one or more chenodeoxycholic acid derivative lipid compounds.

[0018] Specifically, the molecular weight of the polymer in the polymer lipid compound is 200-20000 Daltons.

[0019] Specifically, the polymer in the polymer lipid compound can be a branched molecule or a straight-chain molecule.

[0020] Specifically, the two ends of the polymer in the polymer lipid compound can be one or more of methoxy, amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphate, etc.

[0021] Among them, the connecting molecules (L1, L2) in the polymer lipid compound are the same or different from each other, and are independently selected from: not present, or one or more of the following structures. In addition, the connecting molecules (L1, L2) are connected to both ends through one or more of ester groups, amide groups, carbamate groups, carbonate groups, ether groups or urea groups.

[0022]

[0023] Specifically, L1 and L2 are independently selected from a linear saturated hydrocarbon or unsaturated hydrocarbon of 2-25 carbon atoms, and both ends of the hydrocarbon are one or more of carboxyl, hydroxyl, amino, sulfate, sulfonic acid, and phosphoric acid groups.

[0024] Specifically, L1 and L2 are independently selected from saturated hydrocarbons or unsaturated hydrocarbons containing 3-8 ring members, and both ends of the hydrocarbons are one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups.

[0025] Among them, R4 in the polymer lipid compound can be independently selected from one or more of nucleic acids, small molecules, sugars, antibodies, peptides or other ligands.

[0026] Specifically, the polypeptide includes but is not limited to targeting peptides, protease inhibitors, etc. Further preferably, the targeting peptide includes but is not limited to GALA peptide, etc. Further preferably, the GALA peptide is a targeting peptide composed of 30 amino acids, and its sequence is: WEAALAEALAEALAEHLAEALAEALEALAA. Further preferably, the protease inhibitor is a FAP inhibitor (FAPI).

[0027] The present invention also provides a polymer lipid compound, wherein the polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure:

[0028]

[0029] R1 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl, alkane containing nitrogen atom, alkene containing nitrogen atom, alkane containing oxygen atom

[0030] R2 = hydrogen atom, alkyl group, alkene, alkyne, substituted carbonyl group, alkane containing nitrogen atom, alkene containing nitrogen atom

[0031] R3=hydroxyl group, chlorine atom, alkane, alkene, alkyne

[0032] R4=hydrogen atom, small molecule, antibody, peptide, protein, nucleic acid, carbohydrate

[0033] X = PEG (polyethylene glycol), polysarcosine derivatives, chitosan derivatives, dextran, polylactic acid, polyamino acid-modified phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, dialkylglycerol

[0034] L1, L2 = the same or different, straight / branched alkyl chains or heterocyclic compounds, with one or more of amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphoric acid, and carbonate at both ends.

[0035] Specifically, the polymer lipid compound is a polymer lipid based on bile acid or its derivatives; wherein bile acid or its derivatives are selected from one or more of 3β-hydroxy-D5-cholenic acid, lithocholic acid, deoxycholic acid, 5β-cholic acid, dehydrocholic acid, cholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium taurohyodeoxycholate, sodium dehydrocholate, sodium deoxyglycocholate, sodium taurodeoxycholate, taurocholic acid-3-sulfate disodium salt and sodium taurolithocholic acid.

[0036] Specifically, the lipid compound is lithocholic acid or its derivatives.

[0037] Specifically, the lipid compound is one or more selected from bile acid derivative lipid compounds and one or more hyodeoxycholic acid derivative lipid compounds.

[0038] Specifically, the molecular weight of the polymer in the polymer lipid compound is 200-20000 Daltons.

[0039] Specifically, the polymer in the polymer lipid compound can be a branched molecule or a straight-chain molecule.

[0040] Specifically, the two ends of the polymer in the polymer lipid compound can be one or more of methoxy, amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphate, etc.

[0041] Among them, the connecting molecules (L1, L2) in the polymer lipid compound are the same or different from each other, and are independently selected from: not present, or one or more of the following structures. In addition, the connecting molecules (L1, L2) are connected to both ends through one or more of ester groups, amide groups, carbamate groups, carbonate groups, ether groups or urea groups.

[0042]

[0043] Specifically, L1 and L2 are independently selected from a linear saturated hydrocarbon or unsaturated hydrocarbon of 2-25 carbon atoms, and both ends of the hydrocarbon are one or more of carboxyl, hydroxyl, amino, sulfate, sulfonic acid, and phosphoric acid groups.

[0044] Specifically, L1 and L2 are independently selected from saturated hydrocarbons or unsaturated hydrocarbons containing 3-8 ring members, and both ends of the hydrocarbons are one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups.

[0045] Among them, R4 in the polymer lipid compound can be independently selected from one or more of nucleic acids, small molecules, sugars, antibodies, peptides or other ligands.

[0046] On the other hand, the present invention also provides a polymer lipid compound conjugate, the conjugate mainly consists of three parts: a therapeutic or preventive drug, a linker and a lipid compound as described in any one of the patents. The therapeutic or preventive drug includes nucleic acids, proteins, polypeptides, antibodies, carbohydrates, small molecule compounds, etc.

[0047] Specifically, the nucleic acid of the therapeutic or preventive drug includes DNA and RNA, wherein the DNA may be non-coding DNA or coding DNA, and the RNA may be selected from one or more of ASO, mRNA, siRNA, and micRNA.

[0048] On the other hand, the present invention also provides a method for preparing the polymer lipid compound, which may include a step of reacting using RXY, wherein X, R and Y have the corresponding definitions in the polymer lipid compound scheme of the present invention, and R and Y are reactive groups, for example, hydroxyl, carboxyl, amino, thiol, maleimide, succinimide, alkynyl, azido, aldehyde, epoxy, etc.

[0049] In yet another aspect, the present invention further provides a composition of a polymer lipid compound, which comprises the polymer lipid compound described in the above technical solution or a pharmaceutically acceptable salt, ester, isomer, prodrug and solvate thereof.

[0050] Specifically, the composition includes a therapeutic or preventive agent and a carrier for delivering the therapeutic or preventive agent, and the carrier includes one or more of any polymer lipid compound or its conjugate described in this patent.

[0051] Specifically, the therapeutic or prophylactic agent is encapsulated within or associated with a carrier.

[0052] Specifically, the mass ratio of the carrier to the therapeutic or preventive agent is 1:1 to 100:1.

[0053] Specifically, the therapeutic or preventive agent includes one or more of nucleic acid molecules, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.

[0054] Specifically, the composition is lipid nanoparticles, the average size of the lipid nanoparticles is 20nm to 1000nm; and the polydispersity coefficient of the lipid nanoparticles is ≤0.3.

[0055] Specifically, the nucleic acid includes any form of nucleic acid molecules, including but not limited to single-stranded DNA, double-stranded DNA, short isomers, agomir, antagomir, antisense molecules, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA) and other forms of RNA molecules known in the art, or nucleic acid mimetics such as locked nucleic acids (LNA), peptide nucleic acids (PNA) and morpholino oligonucleotides.

[0056] According to some specific embodiments, the therapeutic or preventive agent comprises at least one mRNA encoding an antigen, protein or peptide, or a fragment or epitope thereof.

[0057] In particular, the mRNA is a monocistronic mRNA or a polycistronic mRNA.

[0058] In particular, the antigen is a pathogenic antigen.

[0059] Specifically, the mRNA contains one or more functional nucleotide analogs, including but not limited to one or more of pseudouridine, 1-methyl-pseudouridine and 5-methylcytosine.

[0060] Specifically, the small molecule compounds include but are not limited to active ingredients of therapeutic and / or preventive agents, which are existing known drugs, such as anti-tumor drugs, anti-infective drugs, local anesthetics, antidepressants, anticonvulsants, antibiotics / antibacterial agents, antifungal drugs, antiparasitic drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-glaucoma agents, anesthetics, or contrast agents.

[0061] Specifically, the carrier comprises at least two different lipid components, wherein at least one of the lipids is a lipid based on bile acid or a derivative thereof.

[0062] Specifically, the carrier also includes one or more of cationic lipids or ionizable lipids, neutral lipids, and steroidal lipids. Specifically, the cationic lipids include but are not limited to 4-(N,N-dimethylamino)butyric acid (dilinoleyl) methyl ester (Dlin-MC3-DMA), 2-di-octadecanoyl-3-trimethylammonium-propane (DOTAP), 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]octanoic acid 1-octylnonyl ester (SM-102), dimethyldi-octadecanoate (DDAB), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol), 1,2-di-tetradecanoyl-3-trimethylammonium-propane (DMTAP), One or more of 1,2-di-(9Z-octadecenoyl)-3-dimethylammonium-propane (DODAP), 1,2-dioleoyl-c-(4'-trimethylammonium)-butyryl-sn-glycerol (DOTB), di-octadecyl-alanyl spermine, SAINT-2, polycationic lipid 2,3-dioleoyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), ((4-hydroxybutyl) azadialkyl) bis(hexane-6,1-diyl) bis(2-hexyldecanoate) (ALC-0315), etc., or derivatives thereof. In particular, ALC-0315.

[0063] Specifically, the composition may further comprise neutral lipids, including but not limited to distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE). , dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE) or a mixture thereof, in particular DSPC.

[0064] Specifically, the composition may further comprise steroidal lipids, including but not limited to avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprosterol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fucosterol, hexahydroluminosterol, hydroxycholesterol; lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, bile acid, glycocholic acid, taurocholic acid, deoxycholic acid and lithocholic acid, one or more thereof. In particular, cholesterol.

[0065] Specifically, the carrier also includes but is not limited to cationic lipids or ionizable lipids, neutral lipids and steroidal lipids; the molar ratio of the cationic lipids or ionizable lipids, neutral lipids, steroidal lipids and the polymer lipid compound of the present invention is (30-80): (5-20): (30-50): (0.2-5), and further preferably, the molar ratio of the cationic lipids or ionizable lipids, neutral lipids, steroidal lipids and the polymer lipid compound of the present invention is (45-55): (7-12): (35-45): (1-2).

[0066] Specifically, the mass ratio of the carrier to the therapeutic or preventive agent is 5:1 to 50:1. Further preferably, the mass ratio of the carrier to the therapeutic or preventive agent is 5:1 to 35:1. Further preferably, the mass ratio of the carrier to the therapeutic or preventive agent is 10:1 to 30:1.

[0067] Specifically, the composition further comprises one or more pharmaceutically acceptable excipients or diluents.

[0068] Specifically, the composition further comprises one or more of a buffer, a carbohydrate, mannitol, a protein, a polypeptide or an amino acid, an antioxidant, an antibacterial agent, a chelating agent, and an adjuvant.

[0069] On the other hand, the present invention also provides a use of any lipid compound, conjugate or composition of the present patent in the preparation of nucleic acid drugs, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.

[0070] Specifically, any lipid compound, conjugate or composition thereof of this patent is used in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, wherein the composition is a lipid nanoparticle having a particle size of 20 to 1000 nm.

[0071] In yet another aspect, the present invention also provides the preparation of the polymer lipid compound or its pharmaceutically acceptable salt, ester, isomer, prodrug and solvate, the conjugate or the composition in a therapeutic or preventive agent delivery system.

[0072] Specifically, a composition for preparing nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, which comprises a nucleic acid and a composition for encapsulating the nucleic acid, wherein the composition is a lipid nanoparticle, wherein each individual lipid nanoparticle comprises a plurality of lipid components, wherein one or two lipid components are bile acid-based lipid compounds, including compounds thereof or pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs thereof, and wherein the lipid nanoparticle has a nucleic acid encapsulation ratio of at least 70%.

[0073] In some embodiments, the lipid nanoparticles are formed by mixing an mRNA solution with a lipid solution of any polymer lipid compound of the present invention or a lipid solution of its conjugate. In some embodiments, the lipid nanoparticles are further purified by tangential flow filtration.

[0074] Specifically, the lipid nanoparticles are formed by mixing an mRNA solution and a lipid solution. The medium of the mRNA solution is HEPES (hydroxyethylpiperazine ethanesulfonic acid buffer), phosphate, acetate, ammonium sulfate, sodium bicarbonate or citrate. The medium of the lipid solution is ethanol, isopropanol or dimethyl sulfoxide. More specifically, the phosphate is such as sodium phosphate. More specifically, the acetate is such as sodium acetate. More specifically, the citrate is such as sodium citrate.

[0075] Specifically, the medium of the lipid solution is ethanol, isopropanol or dimethyl sulfoxide; wherein the lipid nanoparticles are further purified by dialysis or ultrafiltration.

[0076] Specifically, the pharmaceutical composition is a lipid nanoparticle, and the average size of the lipid nanoparticle is 20nm to 1000nm, preferably 40nm to 150nm, further preferably 50nm to 100nm, and more preferably 70nm to 100nm.

[0077] Specifically, the polydispersity index of the lipid nanoparticles is ≤0.5, further preferably ≤0.3, and more preferably ≤0.25.

[0078] Specifically, the lipid nanoparticles have a nucleic acid encapsulation ratio of at least 70%.

[0079] Specifically, the lipid nanoparticles generally also contain one or more pharmaceutically acceptable excipients (e.g., neutral buffered saline or phosphate buffered water), carbohydrates (e.g., glucose, mannitol, sucrose, trehalose, dextrose or dextran), mannitol, proteins, polypeptides or amino acids (e.g., glycine and lysine), antioxidants (vitamin E and butylated hydroxytoluene), antibacterial agents, chelating agents (e.g., EDTA and glutathione), adjuvants (e.g., aluminum hydroxide), suspending agents / thickening agents / preservatives that make the preparation isotonic with the recipient's blood, etc., or the composition of the present invention can be formulated into a lyophilizate.

[0080] On the other hand, the present invention also provides the polymer lipid compound or its pharmaceutically acceptable salt, ester, isomer, prodrug and solvate as described in the above technical scheme, the composition as described in the above technical scheme, and the use of the lipid nanoparticles as described in the above technical scheme in the preparation of drugs for preventing and / or treating diseases, and in preventing and / or treating diseases.

[0081] Specifically, in this method, the administration methods include but are not limited to intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intratumor injection, ocular administration, ear administration, nasal administration, oral administration, anal administration, vaginal administration, etc.

[0082] Specifically, in this method, the subject can be any animal or its cells (in vitro or in situ) that are subjected to the method; more specifically, the subject includes mammals such as cattle, horses, mules, donkeys, camels, pigs, sheep, dogs, foxes, rabbits, etc., poultry such as chickens, ducks, geese, pigeons, etc., fish, non-human primates, and humans.

[0083] Bile acid is a naturally occurring steroid molecule in humans and mammals, synthesized in the liver from cholesterol. After eating, bile acid is actively secreted by liver cells, enters the gallbladder with bile, and then enters the intestine from the gallbladder to play its digestive function. Bile acid enters the small intestine in the form of sodium salt to help digestion and absorption of lipids, and then returns to the liver through the portal vein at the end of the ileum by active absorption or passive transport, is processed and transformed in the liver cells, and then is secreted into the small intestine together with newly synthesized bile acid. This EHC (enterohepatic circulation) process of bile acid will circulate 4 to 12 times a day, and about 95% of bile acid is reabsorbed and utilized. If the EHC of bile acid is destroyed, it will not only affect the digestion and absorption of lipids in the body, but also cause the body to form cholesterol stones. Therefore, the biggest advantage of compound delivery carriers designed based on bile acid is the high efficiency of enterohepatic circulation, which participates in the enterohepatic circulation of bile acid, thereby improving the absorption of drugs in the liver and gallbladder. The structural formula of bile acid is as follows.

[0084]

[0085] The three six-membered rings and one five-membered ring on the steroid skeleton of the bile acid molecule are on the same plane, with ring A and ring B connected in reverse, forming a cavity-like structure. The three methyl groups in the molecule are distributed on one side of the plane where the steroid ring is located, forming the hydrophobic part of the molecule, and the three hydroxyl groups are distributed on the other side of the plane where the steroid ring is located, forming the hydrophilic part of the molecule together with the carboxyl group at position C24.

[0086] The special structure of bile acid molecules determines that it is amphiphilic, acidic and alkaline, and easy to be chemically modified. Therefore, this patent uses bile acid as a building block to prepare polymers or oligomers. These functional molecules based on bile acid have good technical effects in drug delivery.

[0087] Bile acid drugs have been on the market in China or the United States for many years, including ursodeoxycholic acid, obeticholic acid, chenodeoxycholic acid, and tauroursodeoxycholic acid. For example, ursodeoxycholic acid is used to treat cholesterol gallstones and bile reflux gastritis; obeticholic acid is used to treat primary biliary cirrhosis (PBC) for patients who do not respond adequately to or cannot tolerate ursodeoxycholic acid. Many years of clinical application have shown that bile acid compounds have good safety. In addition, bile acid compounds have hydrophilic and lipophilic amphiphilic properties, and the bioavailability of small molecule chemical drugs can be improved by encapsulation or coupling.

[0088] Bile acid compounds and cholesterol belong to the same class of steroid compounds, have similar structures, and have more sites that can be chemically modified. The structural modification of bile acid compounds to prepare new lipid components may replace the ionizable lipids, PEG lipids, and cholesterol in the original four-component LNP to achieve similar or better mRNA delivery effects. This patent studies the construction of lipid nanoparticle carriers based on bile acid analogs and explores their application in mRNA drug delivery. The LNP of the present invention can simplify the production process and reduce costs; at the same time, it is conducive to promoting the localization of nucleic acid drugs.

[0089] Because bile acid or its derivatives are composed of a rigid steroid ring and a fatty side chain, where the steroid ring includes three six-membered rings and one five-membered ring. The side chain structure, steroid ring conformation, number of hydroxyl groups and orientation on the steroid ring of bile acid will be different depending on the source. The common hydroxyl groups of bile acid or its derivatives and the carboxyl groups of the fatty side chains are both good chemical modification sites. Therefore, we believe that bile acid or its derivatives can achieve the desired purpose through some common modifications.

[0090] GALA peptide is a targeting peptide composed of 30 amino acids with the sequence: WEAALAEALAEALAEHLAEALAEALEALAA; GALA peptide is an artificial sequence designed based on the fusion peptide on the viral envelope. It not only has the function of promoting phospholipid membrane fusion, but also has obvious acid sensitivity, which can promote lysosomal escape; it can serve as a pH-dependent endosomal escape inducer and a ligand targeting pulmonary endothelial cells. In this study, GALA-modified PEG lipids were used to replace traditional PEG lipids for the preparation of LNPs to achieve better targeted expression of mRNA.

[0091] Fibroblast activation protein (FAP) is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is highly expressed in many epithelial tumor-associated fibroblasts, such as liver cancer, colorectal cancer, pancreatic cancer and ovarian cancer. It is also highly expressed in lesions characterized by interstitial tissue activation, such as infectious, inflammatory, fibrotic diseases and healing wounds, while it is not expressed or expressed at a low level in normal tissues and benign tumor stroma. FAP inhibitor (FAPI) has a high affinity and specificity for FAP on the surface of fibroblast (CAF) membrane. By utilizing its high affinity and specificity for FAP, FAPI is used to modify PEG lipids instead of traditional PEG lipids for the preparation of LNP to achieve better targeted expression of mRNA.

[0092] The technical solution of the present invention provides a new class of lipid compounds for delivering therapeutic or preventive drugs, namely, lipids based on bile acid or its derivatives. The technical solution of the present invention is different from the existing patented technical solutions of foreign pharmaceutical companies, enriches the types of lipid compounds, and provides more options for the delivery of nucleic acid drugs, gene vaccines, peptides, proteins, antibodies and small molecule drugs, etc., and can be significantly different from the technical routes of Pfizer and Moderna. BRIEF DESCRIPTION OF THE DRAWINGS

[0093] Figure 1 This is the H NMR spectrum of ursodeoxycholic acid derivative (Compound 1).

[0094] Figure 2 This is the H NMR spectrum of ursodeoxycholic acid derivative (Compound 2).

[0095] Figure 3 This is the H NMR spectrum of ursodeoxycholic acid derivative (compound 3).

[0096] Figure 4 This is the H NMR spectrum of the lithocholic acid derivative (Compound 11).

[0097] Figure 5 This is the H NMR spectrum of the lithocholic acid derivative (Compound 14).

[0098] Figure 6 This is a graph showing the expression of fluorescent proteins in mice after intravenous injection.

[0099] Figure 7 This is a graph showing the expression of fluorescent proteins in mice after intramuscular injection.

[0100] Figure 8 This is the H NMR spectrum of compound P001.

[0101] Fig. 9 This is the hydrogen nuclear magnetic resonance spectrum of compound P002.

[0102] Fig.10 This is the hydrogen nuclear magnetic resonance spectrum of compound P003.

[0103] Fig.11 This is a diagram of fluorescent protein expression in mice. DETAILED DESCRIPTION

[0104] It should be noted that some lipid compounds in this patent are cited from some lipid compounds in patents CN2023105292749 and CN2024100484234.

[0105] The polymer lipid compound described in this patent is one or more compounds selected from the following structures;

[0106] ① Ursodeoxycholic acid derivative lipids:

[0107]

[0108]

[0109]

[0110] ② Lithocholic acid derivative lipids:

[0111]

[0112]

[0113] The present invention is further described below in conjunction with the examples, but the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific use, and the implementation conditions not specified are conventional conditions in the industry. The technical features involved in each embodiment of the present invention can be combined with each other as long as they do not conflict with each other.

[0114] Example

[0115] This article uses the following abbreviations:

[0116] BrBn: Benzyl bromide

[0117] TEA: Triethylamine

[0118] HATU: N,N,N',N'-Tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate DIPEA: N,N-diisopropylethylamine

[0119] HBTU: Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0120] mPEG-2000-NH2: methoxy polyethylene glycol amine

[0121] Py: pyridine

[0122] MeCN: Acetonitrile

[0123] DMF: N,N-dimethylformamide

[0124] DCM: Dichloromethane

[0125] MeOH: Methanol

[0126] TLC: Thin layer chromatography

[0127] The present invention is further described in detail below in conjunction with specific embodiments and Tables 1-4, so that those skilled in the art can better understand the present invention and make a clearer and more definite definition of the protection scope of the present invention.

[0128] Example 1: Synthesis of ursodeoxycholic acid derivative (Compound 1):

[0129]

[0130] Synthesis of intermediate 1-1: Add ursodeoxycholic acid (10 g, 25.5 mmol), acetonitrile (100 mL), benzyl bromide (6.5 g, 38.2 mmol) and potassium carbonate (6.9 g, 51 mmol) to the reaction flask in sequence. Then heat to 50 ° C and react overnight. TLC shows that the reaction is complete. The reaction solution is diluted with water, then extracted with ethyl acetate, the organic phase is dried and concentrated, and silica gel column chromatography is performed, eluted with DCM / CH3OH (10:1) to obtain a white solid 1-1 (9.96 g, 81%). 1 HNMR (400MHz, CDCl3) δ7.32-7.36(m,5H),5.08-5.15(m,2H),3.55-3.62(m,2H),0.94(s,3H,CH3),0.91(d,3H,CH3),0.65(s,3H,CH3). HPLC: 98.41%.

[0131] Synthesis of intermediate 1-2: Dissolve the compound 2-hexyldecanoic acid (2.4 g, 9.5 mmol) in DCM (50 mL), add 1 drop of DMF, and then slowly add oxalyl chloride (4.7 g, 37.2 mmol). After the addition, continue to stir and react for 1 h. The reaction solution is directly concentrated to obtain a crude product. The crude acyl chloride is dissolved in DCM and dripped into a reaction bottle containing compound 1-1 (1.5 g, 3.1 mmol), TEA (5.3 mL, 37.2 mmol) and DCM (20 mL), and then stirred at room temperature overnight. After the reaction is completed by TLC detection, add an appropriate amount of water, extract with dichloromethane, dry and concentrate the organic phase, chromatograph on a silica gel column, and elute with DCM / CH3OH (30:1) to obtain a light yellow oil 1-2 (1.7 g, 76.8%). 1 HNMR (400MHz, CDCl3) δ7.37-7.31(m,5H),5.14-5.08(m,2H),4.75-4.67(m,1H),2.45-2.36(m,1H),2.32-2.20(m,2 H),2.02-1.97(m,1H),1.91-1.76(m,5H),0.96(s,3H,CH3),0.92(d,3H,CH3),0.89-0.86(m,6H),0.66(s,3H,CH3).

[0132] Synthesis of intermediate 1-3: Compound 1-2 (400 mg, 0.42 mmol) and Pd / C (40 mg) were dissolved in methanol (10 mL) and stirred at room temperature overnight under a hydrogen atmosphere. After the reaction was completed, the reaction solution was filtered with diatomaceous earth and the mother liquor was concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / CH3OH (20:1), and a colorless oil 1-3 (210 mg, 60%) was obtained. 1 HNMR (400MHz, CDCl3) δ4.73-4.68(m,1H),3.62-3.56(m,1H),2.44-2.36(m,1H),2 .30-2.22(m,2H),0.96-0.93(m,6H,CH3×2),0.89-0.86(m,6H),0.68(s,3H,CH3).

[0133] Synthesis of compound 1: Compound 1-3 (200 mg, 0.32 mmol), mPEG-2000-NH2 (760 mg, 0.38 mmol), HATU (180 mg, 0.48 mmol), TEA (96 mg, 0.95 mmol) were dissolved in DMF (4 mL) and stirred at room temperature overnight. After the reaction was completed by TLC detection, the reaction solution was directly concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / CH3OH (15:1), to obtain an off-white solid 1 (320 mg, 38%). 1 HNMR (400MHz,CDCl3,)δ6.23-6.18(m,1H,NH),4.74-4.66(m,1H),3.82-3.43(m,O-CH2-CH2-O),3.37(s,3H,O-CH3),2.30-2.20(m,2H),0.95(s,3H,CH3),0.94-0.92(m,3H,CH3),0.89-0.85(m,6H,CH3×2),0.67(s,3H,CH3).HPLC:97.7%. The hydrogen nuclear magnetic resonance spectrum of compound 1 is shown in the attached figure of the specification. Figure 1 .

[0134] Example 2: Synthesis of ursodeoxycholic acid derivative (Compound 2):

[0135]

[0136] Ursodeoxycholic acid (200 mg, 0.51 mmol) was dissolved in DMF (10 mL), and HATU (193.71 mg, 0.51 mmol), DIPEA (132 mg, 1.02 mmol), and mPEG-2000-NH2 (1.0 g, 0.51 mmol) were added in sequence. The mixture was stirred at room temperature overnight. After the reaction was completed by TLC, the solvent was removed by vacuum distillation to obtain a crude product. Silica gel column chromatography, eluted with DCM / CH3OH (10:1), and an off-white solid compound 2 (510 mg, 43%) was obtained. 1 HNMR (400MHz,CDCl3,)δ6.26(s,1H),3.82-3.44(m,O-CH2-CH2-O),3.37(s,3H,O-CH3),2.27-2.20(m,2H),0.94-0.92(m,6H,CH3×2),0.67(s,3H,CH3).HPLC:94.93%. The H NMR spectrum of compound 2 is shown in the attached figure of the specification. Figure 2 .

[0137] Example 3: Synthesis of ursodeoxycholic acid derivative (Compound 3):

[0138]

[0139] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by tetradecanoic acid. Off-white solid, yield 45%. 1 HNMR (400MHz,CDCl3,)δ6.31(s,1H),4.81-4.74(m,1H,C7),4.71-4.63(m,1H,C3),3.82-3.45(m,O-CH2-CH2-O),3.37(s,3H,O-CH3),2.26-2.18(m,6H),0.96(s,3H,CH3),0.92-0.90(m,3H,CH3),0.89-0.85(m,6H,CH3×2),0.67(s,3H,CH3).HPLC:93.27%. The hydrogen nuclear magnetic resonance spectrum of compound 3 is shown in the attached figure of the specification. Figure 3 .

[0140] Example 4: Synthesis of ursodeoxycholic acid derivative (Compound 4):

[0141]

[0142] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by stearic acid. Off-white solid, yield 42%. 1HNMR(400MHz,CDCl3,)δ6.19(m,1H),4.81-4.72(m,1H,C7),4.71-4.62(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.37(s,3H,O -CH3), 2.26-2.18(m,6H), 0.96(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.86(m,6H,CH3×2), 0.67(s,3H,CH3). HPLC: 95.15%.

[0143] Example 5: Synthesis of ursodeoxycholic acid derivative (Compound 5):

[0144]

[0145] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by dodecanoic acid. Off-white solid, yield 51%. 1 HNMR(400MHz,CDCl3,)δ6.11(m,1H),4.81-4.72(m,1H,C7),4.71-4.63(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O -CH3), 2.26-2.18(m,6H), 0.96(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.85(m,6H,CH3×2), 0.66(s,3H,CH3). HPLC: 96.54%.

[0146] Example 6: Synthesis of ursodeoxycholic acid derivative (Compound 6):

[0147]

[0148] The synthesis method is similar to that of compound 1, except that the feed ratio of 2-hexyldecanoic acid is increased to 5.0 times. Off-white solid, yield 46%. 1 HNMR(400MHz,CDCl3)δ6.25(m,1H),4.81-4.75(m,1H,C7),4.71-4.65(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O- CH3), 2.26-2.19(m,4H), 0.97(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.85(m,12H,CH3×4), 0.68(s,3H,CH3). HPLC: 91.09%.

[0149] Example 7: Synthesis of ursodeoxycholic acid derivative (Compound 7):

[0150]

[0151] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by acetyl chloride. Off-white solid, yield 57%. 1 HNMR(400MHz,CDCl3,)δ6.08-6.05(m,1H),4.78-4.71(m,1H,C7),4.69-4.61(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H ,O-CH3),2.26-2.18(m,4H),2.01(s,3H),1.97(s,3H),0.96(s,3H,CH3),0.91-0.90(m,3H,CH3),0.66(s,3H,CH3).HPLC: 97.19%.

[0152] Example 8: Synthesis of ursodeoxycholic acid derivative (Compound 8):

[0153]

[0154] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by hexanoyl chloride. Off-white solid, yield 49%. 1 HNMR(400MHz, CDCl3)δ6.11-6.08(m,1H,NH),4.80-4.73(m,1H,C7),4.70-4.61(m,1H,C 3),3.81-3.79(m,1H),3.64-3.63(m,174H,PEG-chain),3.55-3.52(m,5H),3.46-3.41( m,3H),3.36(s,3H,O-CH3),2.25-2.17(m,6H),2.06-1.96(m,2H),1.82-1.24(m,38H),1 .15-1.00(m,3H),0.95(s,3H,CH3), 0.91-0.86(m,9H),0.66(s,3H,CH3). HPLC: 93.65%.

[0155] Example 9: Synthesis of ursodeoxycholic acid derivative (Compound 9):

[0156]

[0157] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by octanoyl chloride. Off-white solid, yield 54%. 1HNMR (400MHz, CDCl3) δ6.11-6.08(s,1H),4.80-4.73(m,1H,C7),4.70-4.61(m,1H,C3),3.81-3.41(m,O-CH2-CH2-O),3.36(s, 3H,O-CH3), 2.25-2.17(m,6H), 2.06-1.96(m,2H), 0.95(s,3H,CH3), 0.91-0.86(m,9H,CH3×3), 0.66(s,3H,CH3). HPLC: 94.13%.

[0158] Example 10: Synthesis of ursodeoxycholic acid derivative (Compound 10):

[0159]

[0160] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by decanoyl chloride. Off-white waxy solid, yield 56%. 1 HNMR(400MHz, CDCl3)δ6.11-6.08(s,1H),4.80-4.73(m,1H),4.62-4.70(m,1H),3.81-3.40(m,O-CH2-CH2-O),3.36(s,3H,O-CH3),2 .25-2.17(m,1H),2.08-2.00(m,2H),1.99-1.96(m,1H),0.95(s,3H,CH3),0.91-0.84(m,9H,CH3×3),0.65(s,3H,CH3). HPLC: 96.65%.

[0161] Example 11. Synthesis of lithocholic acid derivatives (Compound 11):

[0162]

[0163] The synthesis method refers to the synthesis of compound 2, except that ursodeoxycholic acid is replaced by lithocholic acid. Off-white solid, yield 62.9%. 1 HNMR (400MHz,CDCl3,)δ6.12(s,1H),3.82-3.42(m,O-CH2-CH2-O),3.37(s,3H,O-CH3),2.27-2.19(m,1H),2.10-2.02(m,2H),1.96-1.93(m,1H),0.91-0.90(m,6H,CH3×2),0.63(s,3H,CH3).HPLC:97.85%. The hydrogen nuclear magnetic resonance spectrum of compound 11 is shown in the attached figure of the specification. Figure 4 .

[0164] Example 12. Synthesis of lithocholic acid derivative (Compound 12):

[0165]

[0166] Synthesis of intermediate 12-2: Compound 12-1 (10 g, 2.66 mmol) and acetonitrile (200 mL) were added to the reaction flask in sequence, and benzyl bromide (5.9 g, 3.45 mmol) and potassium carbonate (5.5 g, 3.98 mmol) were added under stirring. The reaction solution was heated to 50°C and reacted overnight. TLC showed that the reaction was complete. The reaction solution was filtered, the filtrate was concentrated and dried, and silica gel column chromatography was performed, eluted with DCM / CH3OH (20:1), and an off-white solid 12-2 (10 g, 80%) was obtained. 1 HNMR (400MHz, CDCl3) δ7.37-7.31(m,5H,ArH),5.14-5.08(m,2H,O-CH2-Ph),3.66-3.58(m,1H,C3),2.44-2. 36(m,1H),2.31-2.23(m,1H),1.96-1.92(m,1H),0.91-0.89(m,6H,CH3×2),0.62(s,3H,CH3). HPLC: 98.41%.

[0167] Synthesis of intermediate 12-4: Compound 12-2 (470 mg, 1.0 mmol) and pyridine (8 mL) were added to the reaction flask in sequence, and then the acid chloride 12-3 (490 mg, 3.00 mmol) was slowly added dropwise. After the addition was complete, the reaction was stirred overnight. TLC showed that the reaction was complete. The reaction solution was quenched with water, extracted with dichloromethane, and the organic phase was dried and concentrated. Silica gel column chromatography, eluted with DCM / CH3OH (10:1), and a light yellow oil 12-4 (506 mg, 85.1%) was obtained. 1 HNMR(400MHz, CDCl3)δ7.39-7.31(m,5H,ArH),5.14-5.08(m,2H,O-CH2-Ph),4.77-4.69(m,1H,C3),2.44-2.36(m,1H ), 2.31-2.23(m,1H),1.97-1.93(m,1H),0.92(s,3H,CH3)0.92-0.88(m,6H,CH3×2),0.62(s,3H,CH3). HPLC: 96.85%.

[0168] Synthesis of intermediate 12-5: Add intermediate 12-4 (417 mg, 0.70 mmol), MeOH (6 mL) and Pd / C (150 mg, 35 wt%) to the reaction flask. After hydrogen replacement 3 times, stir the reaction at room temperature overnight. TLC shows that the raw material is completely reacted. The reaction solution is filtered through diatomaceous earth, the filtrate is concentrated, and the silica gel column is chromatographed and eluted with DCM / CH3OH (10:1) to obtain a white solid 12-5 (250 mg, 70%). 1 HNMR (400MHz, CDCl3) δ4.77-4.69(m,1H,C3),2.44-2.36(m,1H),2.30-2.22(m,1H),1.98-1. 94(m,1H),0.93-0.91(s,6H,CH3×2)0.89-0.86(m,3H,CH3),0.64(s,3H,CH3). HPLC: 98.08%.

[0169] Synthesis of compound 12: Add intermediate 12-5 (101 mg, 0.20 mmol) and DMF (2 mL) to the reaction bottle in sequence, stir and dissolve, add compound HBTU (100 mg, 0.26 mmol), DIPEA (80 mg, 0.60 mmol), stir and react for 5 minutes. Add compound mPEG-2000-NH2 (485 mg, 0.24 mmol), stir and react at room temperature overnight. TLC shows that the reaction is complete. The reaction solution is concentrated and chromatographed on a silica gel column. Eluted with DCM / CH3OH (10:1) to obtain an off-white solid 12 (433 mg, 86.3%). 1 HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.67(m,1H,C3),3.81-3.41(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.09-1.99(m,2H),1.96-1.93(m,1H),0.91-0.85(m,9H,CH3×3),0.62(s,3H,CH3). HPLC: 97.10%.

[0170] Example 13. Synthesis of lithocholic acid derivative (Compound 13):

[0171]

[0172] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by decanoyl chloride. Off-white solid, yield 73.2%. 1HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.69(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.09-2.03(m,2H),1.97-1.94(m,1H),0.92-0.85(m,9H,CH3×3),0.63(s,3H,CH3). HPLC: 98.85%.

[0173] Example 14. Synthesis of lithocholic acid derivative (Compound 14):

[0174]

[0175] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by dodecanoyl chloride. Off-white solid, yield 78.6%. 1HNMR (400MHz, CDCl3,) δ 6.19-6.14 (s, 1H), 4.75-4.68 (m, 1H, C3), 3.82-3.42 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.27-2.21 (m, 3H), 2.09-1.99 (m, 2H), 1.97-1.94 (m, 1H), 0.92-0.85 (m, 9H, CH3×3), 0.63 (s, 3H, CH3). HPLC: 98.56%. The hydrogen nuclear magnetic resonance spectrum of compound 14 is shown in the attached figure of the specification. Figure 5 .

[0176] Example 15: Synthesis of lithocholic acid derivative (Compound 15):

[0177]

[0178] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by tetradecanoyl chloride. Off-white solid, yield 67.8%. 1 HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.67(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.07-2.02(m,2H),1.96-1.93(m,1H),0.91-0.85(m,9H,CH3×3),0.62(s,3H,CH3). HPLC: 95.31%.

[0179] Example 16: Synthesis of lithocholic acid derivative (Compound 16):

[0180]

[0181] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by 2-hexyldecanoyl chloride. Off-white solid, yield 55%. 1 HNMR(400MHz,CDCl3,)δ6.16(s,1H),4.81-4.73(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.38(s,3H,O-CH3),2. 24-2.20(m,3H),2.01-1.94(m,2H),0.92(s,3H,CH3),0.91-0.85(m,9H,CH3×3),0.63(s,3H,CH3). HPLC: 94.97%.

[0182] Example 17: Preparation of lipid nanoparticles

[0183] According to the classic formula of SM102: DSPC: cholesterol: PEG lipids with a molar ratio of 50: 38.5: 10: 1.5, DMG-PEG2000 was used as a yang ginseng, and then dissolved in ethanol. Luciferase mRNA (encoding luciferase mRNA) was diluted in 20mM citrate buffer (pH = 4) to obtain an mRNA solution, and a microfluidic device was used to mix the ethanol lipid solution and the mRNA solution in a volume of 1: 3, and liposomes were prepared with a total lipid to mRNA weight ratio of 20: 1. Ethanol was removed by dialysis or tangential flow filtration, and finally stored in a PBS solution, and the lipid nanoparticles were filtered with a 0.22μm sterile filter to obtain the final lipid nanoparticles.

[0184] Example 18: Characterization of lipid nanoparticles

[0185] The particle size (Size), polydispersity index (PDI) and zeta potential (Zeta P) of the particles were determined by dynamic light scattering using a Malvern Zetasizer NanoZS (Malvern Nano Particle Size Tester). The encapsulation efficiency of the lipid nanoparticles was determined using a Quant-it Ribogreen RNA Quantitative Analysis Kit (Thermo Fisher Scientific, UK). As shown in Table 1: The size of the lipid nanoparticles was mostly around 100 nm, the potential of most lipid nanoparticles was around 0 mv, the polydispersity index varied around 0.1, and the encapsulation efficiency was mostly 90%.

[0186] Table 1: Characterization of lipid nanoparticles

[0187]

[0188] Example 19: Preliminary in vitro cell transfection experiment of lipid nanoparticles

[0189] 293T cells were planted in 96-well cell culture plates at a density of 3X10^4 cells / well and grown to 24h to adhere to the wall. Prepared according to the preparation method in Example 17, the compounds in Table 2 were prepared into lipid nanoparticles according to the method in Example 17 and added to the cells. After 24h of culture, a color developing solution was added and the luminescence value of each well was detected by a microplate reader. Table 3 shows that lipid nanoformulations can carry mRNA transfection into 293T cells and express the target fluorescent protein. A and B represent the evaluation results of the compounds and the commercial SM102 lipid formula, respectively. The luminous flux was normalized after multiple ratios. As shown in Table 2, the luminous flux of compound 1, compound 12, compound 13, and compound 14 reached the same level as SM102-LNP, indicating that the newly synthesized PEG lipid can replace DMG-PEG2000.

[0190] Note: A and B represent the normalized results of the ratio of the luminescent flux of the compound lipid to that of SM102-LNP, respectively. The ratio range is as follows:

[0191] A: ≥0.5

[0192] B: ≥0.1 and <0.5

[0193] Table 2: Evaluation results of lipid nanoparticles in vitro cell transfection

[0194] Sample No. Cell result ratio score Compound 1 1.0 A Compound 8 0.8 A Compound 9 0.8 A Compound 10 0.9 A Compound 12 1.0 A Compound 13 1.0 A Compound 14 1.0 A Compound 15 0.8 A Compound 16 0.8 A

[0195] Example 20: Fluorescent protein expression experiment of lipid nanoparticles injected into mice.

[0196] Female SPF BALB / c mice aged 6-8 weeks (n=3) were raised in an SPF animal room at a temperature of 20-26°C, a humidity of 40-70%, and sufficient feed and drinking water. The lipid nanoparticles were prepared by the preparation method of the preparation in Example 17 at a dose of 100 μL (0.05 μg / μL) by intramuscular injection and intravenous administration, and the control group used SM102-LNP for in vivo effect comparison. After 6 hours of administration, 200ul D-luciferin potassium salt with a concentration of 15 mg / ml was intraperitoneally injected, and D-luciferin potassium salt was injected 5 minutes later for in vivo imaging. After all groups of in vivo imaging were completed, D-luciferin potassium salt was injected again, and organ imaging was performed 5 minutes later. A and B represent the results of normalization after multiple ratio of the compound and the commercial SM102-LNP fluorescence expression value. As shown in Table 3, compounds 9, 10, 12, 13, 14, 15, and 16 all exceed the SM102-LNP level at the intramuscular injection site, indicating that our synthetic lipids can replace DMG-PEG2000, effectively deliver mRNA, and efficiently express the target gene protein locally. Table 4 is the comparison result after intravenous injection with the commercial SM102-LNP, as shown in Table 4: Among them, compounds 10, 12, 13, 14, and 15 expressed fluorescence in the abdomen at the level of SM102-LNP, indicating that the PEG series lipid compounds can efficiently express the target gene protein through intravenous injection. Figure 6 and Figure 7 This is a diagram of fluorescent protein expression in mice.

[0197] Note: A and B represent the normalized results of the luminescence values ​​of the compound and SM102-LNP, respectively. The ratio range is as follows:

[0198] A: ≥0.5

[0199] B: ≥0.1 and <0.5

[0200] Table 3: Ratio and score of local fluorescence expression in the muscles of mice after intramuscular injection

[0201]

[0202]

[0203] Table 4: Fluorescence expression ratio and score in the abdomen of mice after intravenous injection

[0204] Sample No. ratio score Compound 8 0.4 B Compound 9 0.2 B Compound 10 0.9 A Compound 12 1.0 B Compound 13 1.6 A Compound 14 0.9 A Compound 15 0.7 A Compound 16 0.4 A

[0205] Example 21: The synthetic route of P001 is as follows:

[0206]

[0207] Synthesis of intermediate 1-2: Dissolve intermediate 1-1 (400 mg, 0.83 mmol) in pyridine (4 mL), protect with nitrogen, cool to 0°C-2°C in an ice bath, add decanoyl chloride (948 mg, 4.97 mmol) dropwise, and naturally warm to room temperature and stir to react overnight. TLC detection, after the reaction is completed, add ethyl acetate (20 mL), wash twice with hydrochloric acid (1M, 20 mL), wash the organic layer once with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the solvent to obtain a crude product. Silica gel column chromatography, eluted with PE / EA (9:1), to obtain a colorless oil (570 mg, 87%).

[0208] 1 HNMR(400MHz, CDCl3,)δ7.39-7.31(m,5H),5.14-5.07(dd,J 1=12Hz, J2=16Hz,2H),4.81-4.74(m,1H),4.71-4.66(m,1H),2.43-2.35(m,1H),2.30-2.1 6(m,5H),2.00-1.95(m,1H),0.96(s,3H,CH3),0.91-0.86(m,9H,CH3×3),0.65(s,3H,CH3).

[0209] Synthesis of intermediate 1-3: Intermediate 1-2 (570 mg, 0.72 mmol) was dissolved in MeOH (8 mL) and THF (8 mL), 10% Pd / C (50 mg, 30% wt) was added, hydrogen was replaced 3 times, and the reaction was stirred at 30°C for 4 h. TLC detection, after the reaction was completed, diatomaceous earth was used to filter, the filter cake was washed with DCM twice, the organic layers were combined, and the solvent was concentrated to obtain a crude product. Silica gel column chromatography, DCM / MeOH (30:1) eluted to obtain a colorless oil (285 mg, 56%).

[0210] 1 HNMR(400MHz, CDCl3,)δ4.82-4.75(m,1H),4.70-4.65(m,1H),2.43-2.35(m,1H),2.29-2.17(m,6H) ,2.04-1.97(m,2H),0.97(s,3H),0.93(d,J=4Hz,3H),0.89-0.86(m,6H),0.68(s,3H).HPLC:99.6%.

[0211] Synthesis of compound P001: Dissolve intermediate 1-3 (200 mg, 0.28 mmol) in DCM / MeCN (8 mL) at room temperature, add methyl-PEG2000 (685 mg, 0.34 mmol), TCFH (104 mg, 0.37 mmol), NMI (58 mg, 0.71 mmol) in sequence, protect with nitrogen, stir at room temperature and react overnight. TLC detection, after the reaction is completed, add MeOH (2 mL), stir at room temperature and react for 10 min. The reaction solution is directly concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / MeOH (25:1), white waxy solid (140 mg, 18%).

[0212] 1 HNMR (400MHz, CDCl3) δ4.80-4.74(m,1H),4.70-4.62(m,1H),4.20(t,J=4Hz,2H),3.80(d,J=4Hz,1H),3.71-3.63(m,198H,PEG-chain),3.54-3.52(m,3H ),3.46-3.44(m,1H),3.36(s,3H),2.39-2.32(m,1H),2.25-2.17(m,5H),2. 02-1.96 (m, 4H), 0.96 (s, 3H), 0.90-0.79 (m, 12H), 0.66 (s, 3H). HPLC: 97.8%.

[0213] The H NMR spectrum of compound P001 is shown in the attached figure of the specification. Figure 8 .

[0214] Example 22: The synthetic route of compound P002 is as follows:

[0215]

[0216] Synthesis of intermediate 12-2: Dissolve intermediate 12-1 (2.0 g, 5.31 mmol) in ACN (40 mL) at room temperature, add intermediate benzyl bromide (1.82 g, 10.62 mmol), K2CO3 (2.94 g, 21.24 mmol) in sequence, protect with nitrogen, stir and react overnight at 60°C. TLC detection, after the reaction is completed, add appropriate amount of water, extract with EA twice, combine the organic layers, dry with anhydrous sodium sulfate, filter, and concentrate the solvent to obtain a crude product. Silica gel column chromatography, eluted with PE / EA (1:1), to obtain a white solid (1.78 g, 72%).

[0217] HPLC purity: 97.33%.

[0218] Synthesis of intermediate 12-4: Dissolve the intermediate myristic acid (293.60 mg, 1.29 mmol) in CAN (10 mL): DCM (5 mL) = 2:1 at room temperature, add TCFH (601.19 mg, 2.14 mmol), N MI (307.87 mg, 3.75 mmol) in sequence, stir for 15 minutes, add 12-2 (500.0 mg, 1.07 mmol), and stir at room temperature for 3 hours. TLC detection, after the reaction is completed, add appropriate amount of water, extract with DCM twice, combine the organic layers, dry over anhydrous sodium sulfate, filter, and concentrate the solvent to obtain a crude product. Silica gel column chromatography, eluted with PE / DCM (1:1), to obtain a white solid (500.0 mg, 68.96%).

[0219] 1 H NMR(400MHz,Chloroform-d)δ7.40–7.30(m,4H),5.11(d,J=2.6Hz,2H),4.73(t,J=5.1Hz,1H),2.38(dd,J=10.1,4.9Hz,1H),2.28(dt,J=1 2.5, 7.3Hz, 3H), 2.00–1.74 (m, 6H), 1.72–1.49 (m, 8H), 1.49–1.16 (m, 32H), 1.07 (m, 6H), 0.96–0.76 (m, 9H), 0.62 (s, 3H). HPLC purity: 96.89%.

[0220] Synthesis of intermediate P002-1: Dissolve intermediate 12-4 (400.0 mg, 0.590 mmol) in MeOH (5 mL), add 10% Pd / C (62.87 mg, 10% wt), replace with hydrogen 3 times, and stir at 30°C to react overnight. TLC detection, after the reaction is completed, filter the filtrate, wash the filter cake with DCM twice, combine the organic layers, and concentrate the solvent to obtain a crude product. Silica gel column chromatography, eluted with DCM / MeOH (20:1), to obtain a white solid (301.0 mg, 86.99%). HPLC purity: 94.34%

[0221] Synthesis of compound P002: The intermediate P002-1 (140 mg, 0.238 mmol) was dissolved in ACN (10 mL): DCM (5 mL) = 2:1, and TCFH (133.85 mg, 0.477 mmol), NMI (

[0222] 68.55mg, 0.835mmol), after stirring for 15 minutes, PEG2000 (610.98mg, 0.310mmol) was added, and the reaction was stirred at room temperature for 3h. TLC detection, after the reaction was completed, an appropriate amount of water was added, extracted twice with DCM, the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / MeOH (20:1), to obtain a white solid (338.0mg, 55.86%)

[0223] 1 H NMR(400MHz,Chloroform-d)δ4.73(s,0H),4.22(t,J=4Hz,2H),3.85–3.80(m,1H),3 .64(s,179H),3.57–3.53(m,2H),3.47(m,1H),3.38(s,3H),2.26(t,J=7.6Hz,3H),1 .96(d,J=11.7Hz,1H),1.77(s,13H),1.71–1.48(m,6H),1.41(d,J=12.4Hz,8H),1.34–1.16(m,31H),1.17–0.97(m,7H),0.97–0.74(m,11H),0.64(s,3H).HPLC purity: 98.12%

[0224] The H NMR spectrum of compound P002 is shown in the accompanying drawing of the specification. Fig. 9 .

[0225] Example 23. The synthetic route of lithocholic acid derivative (Compound P003) is as follows:

[0226]

[0227] Synthesis of compound 12-2: Add compound lithocholic acid (10 g, 2.66 mmol) to a single-necked flask and suspend it in ACN (200 mL). Stir and add compound benzyl bromide (5.9 g, 3.45 mmol), K2CO3 (5.5 g, 3.98 mmol), and KI (880 mg, 0.27 mmol). Stir and react overnight at 70°C. TLC shows that the reaction is complete. The reaction solution is filtered and the filter cake is washed with EA (50 mL). The filtrate is concentrated and pulled dry. Then it is dissolved and diluted with EA (100 mL), and washed twice with clean water and saturated NaCl water (100 mL). Dry and concentrate, silica gel column chromatography, eluted with DCM / MeOH (10:1), and a white solid (5 g, 40%) is obtained. HPLC: 98%.

[0228] Synthesis of compound P003-2: Add compound 12-2 (500 mg, 1.07 mmol) to a single-necked flask and dissolve in DCM / ACN (10 mL / 10 mL). Stir to dissolve. Add compound P003-1 (412 mg, 1.61 mmol), NMI (439 mg, 5.36 mmol), and finally add compound TCFH (751 mg, 1.61 mmol) and stir to react for 12 h at RT. TLC: The reaction is complete. Post-treatment: Add water (3 mL) to the reaction solution to quench the reaction, and concentrate to remove the solvent. The residue is dissolved in DCM (15 mL), washed 3 times with clean water and NaCl water (15 mL), dried and concentrated. Silica gel column chromatography, eluted with PE / DCM (1:1), to obtain a colorless oil (690 mg, 91.4%). HPLC: 96.4%.

[0229] Synthesis of compound P003-3: Compound P003-2 (680 mg, 0.96 mmol) was dissolved in MeOH (15 mL) in a single-necked flask. Pd / C (238 mg, 35% MT) was then added. The mixture was replaced with hydrogen three times. The mixture was stirred at 35°C for 12 h under a hydrogen atmosphere. TLC showed that the reaction of the raw material was complete. The reaction solution was filtered with diatomaceous earth as the filter aid. The filter cake was washed with DCM (10 mL). The filtrate was concentrated and the sample was subjected to silica gel column chromatography. DCM / MeOH (20:1) was used as the elution to obtain a colorless oil (569 mg, 95.9%). HPLC: 99.15%.

[0230] Synthesis of compound P003: Add compound P003-3 (150 mg, 0.24 mmol) to a single-necked flask, dissolve in DCM / ACN (2 mL / 2 mL), stir to fully dissolve, then add compound P003-4 (585 mg, 0.29 mmol), NMI (100 mg, 1.22 mmol), and compound TCFH (171 mg, 0.61 mmol) and stir to react for 12 h. TLC shows that the reaction is complete. Add water (3 mL) to the reaction solution to quench the reaction, and concentrate to remove the solvent. The residue is dissolved in DCM (5 mL), washed 3 times with clean water and NaCl water (5 mL), dried and concentrated. Eluted with DCM / MeOH (10:1) to obtain an off-white waxy solid (400 mg, 62.7%). 1H NMR (400MHz, Chloroform-d) δ4.76 (m, 1H), 4.22 (t, J = 4Hz, 2H), 3.75 (b, 1H), 3.57-3.72 (m, 212H), 3.55 (m, 2H), 3.47 (m, 1H ), 3.38(s,3H), 2.45–2.14(m,3H), 2.06–1.70(m,16H), 1.69–0.98(m,50H), 0.98–0.54(m,13H), 0.64(s,3H). HPLC: 95.86%.

[0231] The H NMR spectrum of compound P003 is shown in the attached figure of the specification. Fig.10 .

[0232] Example 24: The synthetic route of LCA-PEG-GALA (P004) is as follows:

[0233]

[0234] Synthesis of intermediate LCA-PEG2000: Compound P003-3 (85 mg, 0.138 mmol), Mal-PEG2000-NH2 (309 mg, 0.138 mmol), HATU (63 mg, 0.166 mmol), DMAP (25 mg, 0.207 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 15 h. TLC detection showed that the reaction was complete, and the reaction solution was concentrated to obtain a crude product. The crude product was chromatographed on a silica gel column, eluted with DCM / CH3OH (10:1), and concentrated to obtain a white waxy solid product (92 mg, 23.3%).

[0235] 1 HNMR(400MHz, CDCl3)δ6.68(s,1.3H),6.39-6.32(m,1.6H),4.78-4.70(m,1.3H),3.81-3.63(m,158H,PE G-chain),3.56-3.53(m,2H),3.51-3.48(m,1H),3.47-3.44(m,3.3H),0.92-0.85(m,12H),0.63(s,3H).

[0236] Synthesis of the final product LCA-PEG2000-GALA: Compound LCA-PEG2000 (20 mg, 0.007 mmol) and GALA (22 mg, 0.007 mmol) were dissolved in DMF (1 mL) and stirred at room temperature for 15 h. HPLC reverse phase chromatography preparation (mobile phase A: 0.1% water, mobile phase B: acetonitrile, gradient elution B: A = 60:40 to 95:5) was performed and freeze-dried to obtain a white solid product (10 mg, 23.8%).

[0237] MALDI-TOF MS: M+H + + / -n*44=6119.444

[0238] The LCA-PEG2000-GALA compound was named P004

[0239] Embodiment 25:

[0240] The synthetic route of LCA-PEG2000-FAPI (P005) is as follows:

[0241]

[0242] The synthesis method of the intermediate FAPI refers to patent CN113582975A, and 1.3 g of an off-white foamy crude product is obtained, with MS: 451.2.

[0243] Synthesis of intermediate Boc-PEG2000-FAPI: Compound FAPI (164 mg, 0.363 mmol), Boc-NH-PEG2000-COOH (782 mg, 0.363 mmol), HATU (165 mg, 0.436 mmol), DIPEA (281 mg, 2.178 mmol) were dissolved in DMF (3 mL) and stirred at room temperature for 2 h. After TLC detection, the reaction was completed and the reaction solution was concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / CH3OH (10:1+0.5% NH3), to obtain a light yellow oil (670 mg, 71.3%).

[0244] 1HNMR(400MHz, CDCl3)δ8.78(d,J=4.0,0.5H),8.01(d,J=8.0,0.5H),7.74-7.73(m,0.5H),7.49(d,J=4.0,0.5H),7.37(dd,J1= 8.0, J2=4.0,0.5H),4.79-4.77(m,0.5H),4.41-4.26(m,1H),3.81-3.51(m,186H,PEG-chain),3.31-3.28(m,2H),1.43(s,9H).

[0245] Synthesis of intermediate PEG2000-FAPI: Compound Boc-PEG2000-FAPI (400 mg, 0.155 mmol), p-toluenesulfonic acid (104 mg, 0.618 mmol), acetonitrile (4 mL), stirred at 65 ° C for 3 h. After TLC detection, the reaction was completed, and the reaction solution was concentrated to obtain a crude product. Silica gel column chromatography, DCM / CH3OH (10:1 + 0.5% NH3) elution, to obtain a colorless oil (283 mg, 72.5%).

[0246] 1 HNMR (400MHz, CDCl3) δ8.78(d,J=4.0,1H),8.01(d,J=8.0,1H),7.71-7.69(m,2H),7.49(d,J=4.0,1H),7.37(dd,J1=8.0,J2 =4.0,1H),7.10(d,J=8.0,2H),4.80-4.77(m,1H),4.41-4.25(m,2H),3.83-3.61(m,222H,PEG-chain),3.19(d,J=4.0,2H).

[0247] Synthesis of the final product LCA-PEG2000-FAPI: Dissolve the compound PEG2000-FAPI (100 mg, 0.04 mmol), P003-3 (37 mg, 0.06 mmol), HATU (30 mg, 0.08 mmol), and DIPEA (10 mg, 0.08 mmol) in DMF (2 mL) and stir at room temperature for 15 h. After TLC detection, the reaction was completed and the reaction solution was concentrated to obtain a crude product. Silica gel column chromatography, eluted with DCM / CH3OH (10:1+0.5% NH3), obtained a white waxy solid (65 mg, 52.8%).

[0248] 1HNMR(400MHz, CDCl3)δ8.78(d,J=8.0,1H),8.00(d,J=8.0,1H),7.71(br,1H),7.50(d,J=4.0 ,1H),7.37(dd,J1=8.0,J2=4.0,1H),7.15-7.13(m,1H),6.28(br,1H),4.78-4.74(m,1H),4.3 5(d,J=8.0,2H),4.26(s,2H),4.23-4.20(m,2H),3.81-3.53(m,199H,PEG-chain),3.45-3.4 2(m,4H),2.68-2.64(m,2H),2.58-2.54(m,4H),0.92(s,3H),0.90-0.82(m,9H),0.63(s,3H).

[0249] MALDI-TOF MS: M+Na + + / -n*44=3108.046

[0250] The LCA-PEG2000-FAPI compound was named P005

[0251] Example 26. Preparation of lipid nanoparticles

[0252] According to the classic formula of SM102: DSPC: cholesterol: PEG lipids with a molar ratio of 50: 38.5: 10: 1.5, DMG-PEG2000 was used as a yang ginseng, and then dissolved in ethanol. Luciferase mRNA (encoding luciferase mRNA) was diluted in 20mM citrate buffer (pH = 4) to obtain an mRNA solution, and a microfluidic device was used to mix the ethanol lipid solution and the mRNA solution in a volume of 1: 3, and liposomes were prepared with a total lipid to mRNA weight ratio of 20: 1. Ethanol was removed by dialysis or tangential flow filtration, and finally stored in a PBS solution, and the lipid nanoparticles were filtered with a 0.22μm sterile filter to obtain the final lipid nanoparticles.

[0253] Example 27. Characterization of lipid nanoparticles

[0254] The particle size (Size), polydispersity index (PDI) and zeta potential (Zeta P) of the particles were determined by dynamic light scattering using a Malvern Zetasizer NanoZS (Malvern Nano Particle Size Tester). The encapsulation efficiency of the lipid nanoparticles was determined using a Quant-it Ribogreen RNA quantitative analysis kit (Thermo Fisher Scientific, UK). As shown in Table 5: The size of the lipid nanoparticles was mostly around 100 nm, the polydispersity index varied around 0.1, and the encapsulation efficiency was mostly 90%.

[0255] Table 5: Characterization of lipid nanoparticles

[0256]

[0257] Example 28. Preliminary in vitro cell transfection experiment of lipid nanoparticles

[0258] 293T cells were planted in 96-well cell culture plates at a density of 3X10^4 / well and grown to 24h to adhere to the wall. Prepared according to the preparation method in Example 17, the compounds in Table 4 were prepared into lipid nanoparticles according to the method in Example 17 and added to the cells. After 24h of culture, a color developing solution was added and the luminescence value of each well was detected by a microplate reader. Table 6 shows that lipid nanoparticles can carry mRNA transfection into 293T cells and express the target fluorescent protein. A and B represent the evaluation results of the compound and the commercial SM102 lipid formula, respectively. The luminous flux was normalized after multiple ratios. As shown in Table 6, the luminous flux of compound P001, compound P002, compound P003, compound P004, and compound P005 reached the same level as SM102-LNP, indicating that the newly synthesized PEG lipid can replace DMG-PEG2000.

[0259] Note: A and B represent the normalized results of the ratio of the luminescent flux of the compound lipid to that of SM102-LNP, respectively. The ratio range is as follows:

[0260] A: ≥0.5

[0261] B: ≥0.1 and <0.5

[0262] Table 6: Evaluation results of lipid nanoparticles in vitro cell transfection

[0263] Sample No. Cell result ratio score Compound P001 1 A Compound P002 0.96 A Compound P003 1 A Compound P004 0.9 A Compound P005 1.1 A

[0264] Example 29. Fluorescent protein expression experiment of lipid nanoparticles injected into mice.

[0265] Female SPF BALB / c mice aged 6-8 weeks (n=3) were raised in an SPF animal room at a temperature of 20-26°C, a humidity of 40-70%, and sufficient feed and drinking water. The lipid nanoparticles were prepared by the preparation method of the preparation in Example 17 at a dose of 100 μL (0.05 μg / μL) by intramuscular injection and intravenous administration, and the control group used SM102-LNP for in vivo effect comparison. After 6 hours of administration, 200ul D-luciferin potassium salt with a concentration of 15 mg / ml was intraperitoneally injected, and D-luciferin potassium salt was injected 5 minutes later for in vivo imaging. After all groups of in vivo imaging were completed, D-luciferin potassium salt was injected again, and organ imaging was performed 5 minutes later. A and B represent the results of normalization after multiple ratio of the fluorescence expression values ​​of the compounds and the commercial SM102-LNP. As shown in Table 7, compounds P001 and P002 exceeded the SM102-LNP level at the injection site of intramuscular injection, indicating that our synthesized lipids can replace DMG-PEG2000, effectively deliver mRNA, and efficiently express the target gene protein locally. Table 8 is the comparison result after intravenous injection with the commercial SM102-LNP, as shown in Table 8: Among them, compounds P001 and P002 expressed fluorescence in the abdomen at the level of SM102-LNP, indicating that the PEG series lipid compounds can efficiently express the target gene protein through intravenous injection. Fig.11 This is a diagram of fluorescent protein expression in mice.

[0266] Note: A and B represent the normalized results of the luminescence values ​​of the compound and SM102-LNP, respectively. The ratio range is as follows:

[0267] A: ≥0.5

[0268] B: ≥0.1 and <0.5

[0269] Table 7: Ratio and score of local fluorescence expression in the muscles of mice after intramuscular injection

[0270]

[0271] Table 8: Fluorescence expression ratio and score in the abdomen of mice after intravenous injection

[0272]

[0273] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A polymer lipid compound, characterized in that The polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure:

2. The polymer lipid compound according to claim 1, characterized in that Wherein bile acid or its derivative is selected from cholic acid, obeticholic acid, ursodeoxycholic acid, ursolic acid, 3β-hydroxy-D5-cholenic acid, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, taurocholic acid, 5β-cholic acid, dehydrocholic acid, hyocholic acid, glycochenodeoxycholic acid, tauroursodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium tauroursodeoxycholate, sodium dehydrocholate, sodium cholate, sodium deoxyglycocholate, sodium taurodeoxycholate, sodium taurocholate, sodium tauroursodeoxycholate, sodium glycocholic acid sodium salt, taurocholic acid-3-sulfate disodium salt, sodium tauroursodeoxycholate and sodium taurolithocholate.

3. The polymer lipid compound according to claim 2, characterized in that The lipid compound is ursodeoxycholic acid or its derivatives, or lithocholic acid or its derivatives.

4. The polymer lipid compound according to claim 1, characterized in that The polymer molecular weight of the polymer lipid compound is 200-20000 Daltons; The two ends of the polymer in the polymer lipid compound are one or more of methoxy, amino, carboxyl, hydroxyl, sulfhydryl, sulfate, sulfonic acid and phosphate.

5. The polymer lipid compound according to claim 1, characterized in that The linking molecules (L1, L2) in the polymer lipid compound are identical or different and are independently selected from: not present, or one or more of the following structures. In addition, the linking molecules (L1, L2) are connected to both ends via one or more of an ester group, an amide group, a carbamate group, a carbonate group, an ether group or a urea group; 6. A polymer-lipid compound conjugate, characterized in that: The conjugate is mainly composed of three parts: a therapeutic or preventive drug, a linker and a lipid compound as described in any one of claims 1-5. The therapeutic or preventive drugs include nucleic acids, proteins, polypeptides, antibodies, carbohydrates, small molecule compounds, etc.

7. The polymer-lipid compound conjugate according to claim 6, characterized in that: The nucleic acid of the therapeutic or preventive drug includes DNA and RNA, wherein the DNA may be non-coding DNA or coding DNA, and the RNA may be selected from one or more of ASO, mRNA, siRNA, and micRNA.

8. A composition of a polymer lipid compound, characterized in that: The composition comprises a therapeutic or preventive agent and a carrier for delivering the therapeutic or preventive agent, wherein the carrier comprises one or more of the polymer lipid compounds or conjugates thereof as described in claims 1 to 7.

9. The composition according to claim 8, characterized in that The therapeutic or preventive agent includes one or more of nucleic acid molecules, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs; The mass ratio of the carrier to the therapeutic or preventive agent is 1:1 to 100:

1.

10. The composition according to claim 8, characterized in that The composition is lipid nanoparticles, and the average size of the lipid nanoparticles is 20nm to 1000nm.

11. The composition according to claim 8, characterized in that The carrier comprises at least two different lipid components, wherein at least one lipid is a lipid based on bile acid or a derivative thereof.

12. The composition according to claim 8 or 11, characterized in that The carrier also includes one or more of cationic lipids or ionizable lipids, neutral lipids, and steroidal lipids.

13. The composition according to claim 8, characterized in that The carrier also includes but is not limited to cationic lipids or ionizable lipids, neutral lipids and steroidal lipids, and the molar ratio of the cationic lipids or ionizable lipids, the polymer lipids, the neutral lipids and the steroidal lipids is (30-80): (0.2-5): (5-20): (30-50).

14. The composition according to claim 8, characterized in that The composition may further comprise one or more pharmaceutically acceptable excipients or diluents.

15. Use of the lipid compound, conjugate or composition according to any one of claims 1 to 14 in the preparation of nucleic acid drugs, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.

16. The lipid compound, conjugate or composition according to any one of claims 1 to 14 is used in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, wherein the composition is lipid nanoparticles having a particle size of 20 to 1000 nm.

17. A composition for preparing nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, comprising a nucleic acid and a composition for encapsulating the nucleic acid, wherein the composition is a lipid nanoparticle, wherein each individual lipid nanoparticle comprises a plurality of lipid components, wherein one or two lipid components are bile acid-based lipid compounds, including compounds thereof or pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs thereof, and wherein the lipid nanoparticle has a nucleic acid encapsulation ratio of at least 70%.

18. A method for preparing the composition of claim 16, wherein the lipid nanoparticles are formed by mixing an mRNA solution with a lipid solution comprising a polymer lipid compound according to any one of claims 1 to 7 or a lipid solution of a conjugate thereof, wherein the medium of the mRNA solution is HEPES (hydroxyethylpiperazine ethanesulfonic acid buffer), sodium phosphate, sodium acetate, ammonium sulfate, sodium bicarbonate or sodium citrate; the medium of the lipid solution is ethanol, isopropanol or dimethyl sulfoxide; wherein the lipid nanoparticles are further purified by dialysis or ultrafiltration.

19. The composition according to claim 14, further comprising one or more of a buffer, a carbohydrate, mannitol, a protein, a polypeptide or an amino acid, an antioxidant, an antibacterial agent, a chelating agent, and an adjuvant.

20. The composition according to claim 13, wherein the administration method comprises intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intratumor injection, ocular administration, ear administration, nasal administration, oral administration, anal administration or vaginal administration.

21. The composition according to claim 13, wherein the administration subject comprises mammals such as cattle, horses, mules, donkeys, camels, pigs, sheep, dogs, foxes or rabbits, birds such as chickens, ducks, geese or pigeons, fish, non-human primates or humans.

22. A polymer lipid compound, characterized in that The polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure:

23. The polymer lipid compound according to claim 22, characterized in that The bile acid or its derivative is optionally one or more of 3β-hydroxy-D5-cholenic acid, lithocholic acid, deoxycholic acid, 5β-cholic acid, dehydrocholic acid, cholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium taurohyodeoxycholate, sodium dehydrocholate, sodium deoxyglycocholate, sodium taurodeoxycholate, taurocholic acid-3-sulfate disodium salt, and sodium taurolithocholic acid.

24. The polymer lipid compound according to claim 23, characterized in that The lipid compound is lithocholic acid or its derivatives.

Citation Information

Cited By

  • Asymmetric branched peg-modified lipid compound, preparation method therefor and use thereof

    WO2026158650A1